{"id": "1340213109026385920", "creation": 1608366679.0, "user_id": "1233901069366771712", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 1, "reply_count": 0, "like_count": 1, "quote_count": 0}}, "text": "J&amp;J, Novavax and CureVac in a Race for #4 Spot.\n\n$AZN is filing for approval with its 2 full-dose 62% efficacy result leaving race on for #4 spot. $JNJ can win the race with its single dose on a strong result\n\n$CVAC $NVAX $BNTX #COVID19 #vaccine #investors https://t.co/p611GmChnd", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE", "#INVESTORS"]}